- Arbutus to Present Imdusiran Data at EASL Congress 2024
- Arbutus to Participate in Two Upcoming Investor Conferences
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
- Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
- Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
- Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
- Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.42 |
---|---|
High | 3.44 |
Low | 3.23 |
Bid | 3.28 |
Offer | 3.39 |
Previous close | 3.28 |
Average volume | 891.14k |
---|---|
Shares outstanding | 188.72m |
Free float | 146.66m |
P/E (TTM) | -- |
Market cap | 618.99m USD |
EPS (TTM) | -0.4393 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼